title: Subcutaneous recombinant human erythropoietin in children with renal anemia on continuous ambulatory peritoneal dialysis.
abstract: Subcutaneous recombinant human erythropoietin (rHuEpo) treatment of renal anemia was performed in four boys and eight girls on CAPD, aged 0.8-12.5 (mean 7.4) years. In contrast to previous studies, our therapeutic goal was not set with a hematocrit of 30% but with full correction of anemia. Following a maximum weekly rHuEpo dosage of median 120 (range 100-240) IU/kg body weight, hematocrit increased in 10 children from 24 (14-29)% within 12 (4-17) weeks to 40.1 (33.5-48.4)%. The weekly increase in hematocrit was 1.27 (0.5-3.1)%. The corrected reticulocyte count increased from 1.3 (0.7-1.8)% to 2.3 (1.4-3.9)% within 4 (2-6) weeks. Eight children fulfilled the protocol; six with an uncomplicated course were able to maintain a hematocrit of 37.1 (35.1-42.7)% with only one sc medication per week of approximately two-thirds of their highest weekly rHuEpo dosage. No serious adverse effect of rHuEpo therapy was observed.
authors.affiliation: Department of Pediatrics, University of Vienna, Austria.
authors.forename: C
authors.initials: C
authors.lastname: Aufricht
authors.forename: E
authors.initials: E
authors.lastname: Balzar
authors.forename: H
authors.initials: H
authors.lastname: Steger
authors.forename: M A
authors.initials: MA
authors.lastname: Lothaller
authors.forename: K
authors.initials: K
authors.lastname: Frenzel
authors.forename: C
authors.initials: C
authors.lastname: Kohlhauser
authors.forename: H
authors.initials: H
authors.lastname: Kiss
authors.forename: A E
authors.initials: AE
authors.lastname: Khoss
authors.forename: T
authors.initials: T
authors.lastname: Kernova
mesh_terms: D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D001835:Body Weight / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006400:Hematocrit; D006801:Humans; D007223:Infant; D007279:Injections, Subcutaneous; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications* / Q000628:therapy; D008297:Male; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D017701:Reticulocyte Count / Q000187:drug effects
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin